Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $BIOD Video Chart 10-04-16 * *
Link to Video - click here to watch the technical chart video
Anyone knows the share structure? There'll be reverse split after merger!
Unilife MedImmune
Took them assets for cheap over a back-door-trap ? Albireo as a key. Geeez1
Will AstraZeneca take the biodel assets into account ? $$$ GLTA $$$
AZ Diabetes Hub
Think ist Couleur Jump in .10 Cents Periodes
$BIOD Now @ $.519 +0.053 +11.37% on 83,000 shares in After Hours trading.
Finally the BIG MOVE UP is being made!
http://www.nasdaq.com/symbol/biod/after-hours
I'm awake. Where do u think this is going after the new ticker symbol
Wake up!
http://forextv.com/top-news/albireo-announces-positive-top-line-phase-3-results-for-elobixibat-in-japan/
Biodel -> Albireo
Biod entered into. Licensing and asset purchase w Unilife. Yaytyy
Woah.. some activity in the aftermarket...
Not sure but I think in near future I think it's in a pr or fillings
That's old news. Do we know where they are currently in this deal?
Very good investment...... That's what I was thinking
Merger with Albireo! :
http://investor.biodel.com/releasedetail.cfm?ReleaseID=972694
Settlement with Unilife? :
http://civilinquiry.jud.ct.gov/CaseDetail/PublicCaseDetail.aspx?DocketNo=DBDCV156018082S
- pipeline sell to interested firms?
- more than 30 mill. cash
- Albireo program very very interesting
http://www.albireopharma.com/programs/
->> Biodel is a very good investment
I'm not sure but I thing they are supposed to merge with a private company soon. When they do they will have a new name. I'm hoping this will be a good move.
On a side note I do notice a possible trend leading to a spike in pps coming with in year end. To what degree..I'm not sure. Opinions on what I just mentioned?
Can anyone tell me or does anyone know what's going here with biodel? Super curious right now.
Is this a good move?
BIOD: STEM-clone on merger. Naked shorts in trouble...eom.
Has symbol change already occurred?
Biodel Inc.(BIOD) AH Trading $.43990 +.0498 +12.77%
Aug. 16, 2016 Market Close: $ 0.3901
After Hours Close: .44 +12.77%
After Hours Volume: 31,741
After Hours High: $ .4898 (16:35:35 PM)
After Hours Low: $ .42 (17:53:50 PM)
http://www.nasdaq.com/symbol/biod/after-hours
STEM deal puts BIOD InPlay. New Nasdaq ticker is ALBO
Millions of shares are naked short.
The STEM blow out today is already moving BIOD in AHs.
BIOD moves big in coming sessions.
BIOD @ .4498 getting serious action now in AHs
That's old news and any jump in share price should have already occurred.
Got a link to that "PENDING MERGER" you refer to ???
Am guessing answer is "NO"
BIOD: Pending merger sets up a STEM-like move.
Buy as much as you can.
BIOD is in the exact same position as STEM.
There are MILLIONS of shares held by naked shorts.
The insanity started today and will only get nuttier.
Whats going on right now? Is there something we don't know about?
BIOD bullish 0.4165
cup and handle chart pattern
http://www.google.com/search?q=cup+and+handle+chart+pattern&hl=en&biw=2000&bih=958&site=webhp&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjs0vv96JPOAhVB8IMKHaHPDEcQsAQIMA&dpr=0.8
macd crossing up over 0 recently
obv uptrending making new highs lately
If she breaks .40 and continues should be a fun ride.
Bid buys .40
it never ran....
* * $BIOD Video Chart 05-31-16 * *
Link to Video - click here to watch the technical chart video
* * $BIOD Video Chart 05-27-16 * *
Link to Video - click here to watch the technical chart video
What a joke - look the chart picture above.
Tells you all.......
* * $BIOD Video Chart 05-26-16 * *
Link to Video - click here to watch the technical chart video
I'm out. Good luck for those that wait.
R/S are a major buzzkill
The longer you wait the better it will be. Biod
Yeh, I waited all these months for this? I really no how to pick them.
That kills all chance of making any money on this stock. Nothing kills shareholder value better than a reverse split.
Followers
|
50
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2118
|
Created
|
03/04/09
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=BIOD
Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis in the United States. The company develops its product candidates by utilizing its proprietary VIAdel technology. It has two insulin product candidates in clinical trials for the treatment of diabetes, including VIAject and VIAtab. VIAject is an injectable formulation of recombinant human insulin, which is in pivotal Phase III clinical trials in patients with Type 1 and Type 2 diabetes. VIAtab is a sublingual tablet formulation of insulin, which is in Phase I clinical trial in patients with Type 1 diabetes. Biodel also has two preclinical product candidates for the treatment of osteoporosis comprising VIAmass, a sublingual formulation of parathyroid hormone 1-34; and VIAcal, a sublingual formulation of salmon calcitonin. The company was founded in 2003 and is based in Danbury, Connecticut.
3/15/2011 March 14, 2011, Biodel Inc. Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins
Biodel Inc. announced that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins. Biodel plans to test these formulations in a Phase 1 clinical trial of approximately 18 patients with Type 1 diabetes. This study is designed as a double blinded, three-period cross over trial in which patients will receive one subcutaneous injection of BIOD-105, BIOD-107 and Humalog(R) each on separate occasions. This study, expected to be completed in the third calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and tolerability profiles of the two experimental insulins relative to that of Humalog(R). In parallel with this subcutaneous injection study, Biodel plans to utilize a similar design to conduct a clinical pump study this year. If this Phase 1 study is successful, Biodel now anticipates initiating a Phase 2 study in patients with Type 1 diabetes in the fourth calendar quarter of 2011. The Phase 2 study is intended to follow the same overall design that would be implemented in Phase 3 studies, which would include two separate pivotal trials-- one in patients with Type 1 diabetes, and the other in patients with Type 2 diabetes. Biodel recently received initial guidance from the U.S. Food and Drug Administration (FDA) on the design of two pivotal Phase 3 clinical trials. Based on this guidance, Biodel plans to design the Phase 2 and 3 studies as randomized parallel group studies using Humalog(R) as a comparator in which active dose titration will occur in the first two months after randomization followed by three months of relatively stable dosing. In these studies, Biodel plans to evaluate efficacy using HbA1c as well as measures of postprandial glucose profiles. If the results of the Phase 2 testing are successful, the company plans to launch Phase 3 pivotal studies required for approval in 2012 rather than its previous guidance of 2013.
Coverage:
http://finance.yahoo.com/q/ud?s=BIOD
Blogs:
http://seekingalpha.com/article/227766-biodel-upside-from-potential-linjeta-approval?source=yahoo
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |